TY - JOUR T1 - Both moderate and severe exacerbations accelerate physical activity decline in COPD patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02110-2017 VL - 51 IS - 1 SP - 1702110 AU - Demeyer, Heleen AU -Costilla -Frias，Marcos au -Louvaris，Zafeiris au -Gimeno -Santos，Elena Au -Tabberer，Maggie Au -Rabinovich，Roberto A. Au Au -de Jong -de Jong，Corina au -polkey- Polkey- Polkey- Polkey，Michael I. Au -I. Au -I. Au-霍普金森，Nicholas S. Au，Nicholas S. Au-Karlsson，Niklas au -Serra，Ignasi au -Vogiatzis，ioannis au -troasters，Thierry au -garcia -aymerich，Judith A2-，Y1-2018/01/01 UR -HTTP：//http：//www.qdcxjkg.com/content/51/1/1702110.Abstract N2-体育活动（PA）是慢性阻塞性肺部疾病（COPD）的相关结果度量。低PA是普遍的，并驱动预后[1]。不幸的是，PA的决定因素及其随着时间的变化知之甚少[1]。PA随着时间的流逝而随着肺功能和健康状况的恶化而逐渐下降的事实表明，PA下降可能是由于疾病的进展，特别是由于急性加重[3]。据报道，在需要住院治疗的严重加重和卧床治疗的恶化[5，6]中，急性减少了PA的急性减少。出院后1个月，已经显示出持续的PA降低[4]，而在社区治疗的加重后，PA几乎恢复到稳定的水平[6]。一项研究发现，在研究前的12个月中，患有两种或更多病史的患者的PA下降速度更快[5]。该分析没有针对关联的混杂因素（例如气流阻塞，症状负担）或影响PA的外部变量（例如气候）。 It could also be argued that the greater decline in PA was due to lower health status at baseline. Although PA is an important outcome for COPD patients, little is known about the role of exacerbations in patients' experience of PA. Importantly, both the amount of activity and difficulties experienced during activity are integral to the concept of PA limitation [7]. The aim of the present analysis was to assess the association between the number and severity of exacerbations and changes in PA and PA experience.Exacerbations have a negative impact on long-term daily physical activity of COPD patients http://ow.ly/olGl30hkdMlWe are grateful for the input from the PROactive project ethics board, advisory board and patient input platform. The PROactive Consortium members are as follows: Nathalie Ivanoff (Almirall, Barcelona, Spain); Niklas Karlsson and Solange Corriol-Rohou (AstraZeneca AB, Gothenburg, Sweden); Ian Jarrod (British Lung Foundation, London, UK); Damijen Erzen (Boehringer Ingelheim, Nieder-Ingelheim, Germany); Mario Scuri and Roberta Montacchini (Chiesi Farmaceutici S.A., Parma, Italy); Paul McBride (Choice Healthcare Solutions, Hitchin, UK); Nadia Kamel (European Respiratory Society, Lausanne, Switzerland); Maggie Tabberer (GlaxoSmithKline, Uxbridge, UK); Thierry Troosters, Wim Janssens, Heleen Demeyer and Fabienne Dobbels (Katholieke Universiteit Leuven, Leuven, Belgium); Judith Garcia-Aymerich (ISGlobal, Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain); Pim de Boer (Netherlands Lung Foundation, Amersfoort, The Netherlands); Karoly Kulich (Novartis, Basel, Switzerland); Michael I. Polkey and Nick S. Hopkinson (Royal Brompton and Harefield NHS Foundation Trust, London, UK); Ioannis Vogiatzis (Thorax Research Foundation, Athens, Greece); Enkeleida Nikai (UCB, Brussels, Belgium); Thys van der Molen and Corina De Jong (University Medical Center, Groningen, The Netherlands); Roberto A. Rabinovich and Bill MacNee (University of Edinburgh, Edinburgh, UK); Milo A. Puhan and Anja Frei (University of Zurich, Zurich, Switzerland). ER -